O’Melveny Advises on Ribo Life Science’s US$235 Million Hong Kong IPO—The Second Largest Since 2022 and the Firm’s 21st Chapter 18A Listing Transaction
January 9, 2026
FOR IMMEDIATE RELEASE
HONG KONG—January 9, 2026—O’Melveny represented joint sponsors and other underwriters in the initial public offering and listing of Suzhou Ribo Life Science Co., Ltd. ("Ribo Life Science", 6938.HK) on the Main Board of the Hong Kong Stock Exchange. The offering size was approximately HK$1.83 billion (approximately US$235 million) following the full exercise of the offer size adjustment option prior to the listing.
The firm represented joint sponsors CICC Hong Kong Securities and Citigroup Global Markets, and other underwriters including ICBCI, BOCI, Macquarie Capital, and ABCI.
Ribo Life Science is a global pioneer in oligonucleotide therapeutics, committed to the development of RNA interference (RNAi) drugs through its vertically integrated R&D platform that spans early research to commercialization. The core product, RBD4059, is a novel siRNA therapy for thrombotic diseases. Its drug pipeline covers major therapeutic areas, including cardiovascular, metabolic, renal, liver, and other diseases.
The transaction is the second largest Chapter 18A Hong Kong IPO since 2022 (in terms of total funds raised), and is also O’Melveny’s 21st Chapter 18A listing. O’Melveny has advised on a quarter of all biotech companies IPOs since the Chapter 18A of Hong Kong’s Main Board Listing Rules were adopted in 2018.
The O’Melveny team was led by partners Ke Geng and Ke Zhu. The core team members included counsel Stella Hu and Jerry Gao, associates Berton Wang, Jingwei Huang and Fan Wu, legal consultants Jie Lian and Audrey Zhan, trainee solicitors Cheryl Chan, and legal consultant intern Willing Lin. Trainee solicitors Bianca Cheng, Priscilla Yeung and Wilson Tang also made valuable contributions.
About O’Melveny
It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at www.omm.com; learn more in our firm at-a-glance; and find us on LinkedIn, Facebook, Instagram, and YouTube.
Contact:
Brandon Jacobsen
O’Melveny & Myers LLP
+1 213 430 8024
bjacobsen@omm.com
Chris Schob
O’Melveny & Myers LLP
+86 21 2307 7000
cschob@omm.com
# # #